대한한방내과학회지 (The Journal of Internal Korean Medicine)

대한한방내과학회 (The Society of Internal Korean Medicine)
권호 표지
DOI QR코드

DOI QR Code

재발 난소암에서 자음강화탕 투여를 통한 Liposomal Doxorubicin, Carboplatin병합요법 부작용 경감 효과

Reduction of Adverse Effects from Jayeumganghwa-tang for Pegylated Liposomal Doxorubicin and Carboplatin in Recurrent Ovarian Cancer

  • 투고 : 2019.11.22
  • 심사 : 2019.12.27
  • 발행 : 2019.12.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: The aim of this study was to report the effects of herbal medicine Jayeumganghwa-tang on reducing the major side effects of doxorubicin and carboplatin in the treatment of ovarian cancer. Methods: The clinical outcomes for a 61-year-old patient treated with Jayeumganghwa-tang for the side effects of doxorubicin and carboplatin combination were recorded by self-evaluation. Results: In the treatment of adverse events caused by chemotherapy, the administration of Jayeumganghwa-tang showed a tendency to reduce their incidence and severity. Conclusions: This study suggests that Jayeumganghwa-tang may be a promising treatment for reducing the side effects of chemotherapy in patients with ovarian cancer.

키워드

참고문헌

  1. KOSIS, Incidence of 61 Cancers by Sex and 5-Year Age Groups [serial online] 2019 Jan 15 [cited 2019 Jul 25]. Available from: URL: http://kosis.kr/statHtml/statHtml.do?orgId=117&tblId=DT_117N_A00121
  2. Henderson JT, Webber EM, Sawaya GF. Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2018;319(6):595-606. https://doi.org/10.1001/jama.2017.21421
  3. Rossi L, Verrico M, Zaccarelli E, Papa A, Colonna M, Strudel M, et al. Bevacizumab in ovarian cancer: A critical review of phase III studies. Oncotarget 2016;8(7):12389-405. https://doi.org/10.18632/oncotarget.13310
  4. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers 2016;2:16061. https://doi.org/10.1038/nrdp.2016.61
  5. Staropoli N, Ciliberto D, Botta C, Fiorillo L, Grimaldi A, Lama S, et al. Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and meta-analysis of randomized trials. Cancer Biol Ther 2014;15(6):707-20. https://doi.org/10.4161/cbt.28557
  6. Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol 2012;1(1):10. https://doi.org/10.1186/2162-3619-1-10
  7. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Saf 1995;13(4):228-44. https://doi.org/10.2165/00002018-199513040-00003
  8. Chen D, Zhao J, Cong W. Chinese Herbal Medicines Facilitate the Control of Chemotherapy-Induced Side Effects in Colorectal Cancer: Progress and Perspective. Front Pharmacol 2018;9:1442. https://doi.org/10.3389/fphar.2018.01442
  9. Yamakawa J, Motoo Y, Moriya J, Ogawa M, Uenishi H, Akazawa S, et al. Role of Kampo medicine in integrative cancer therapy. Evid Based Complement Alternat Med 2013;2013:570848.
  10. Yamakawa J, Motoo Y, Moriya J, Ogawa M, Uenishi H, Akazawa S, et al. Significance of Kampo, traditional Japanese medicine, in supportive care of cancer patients. Evid Based Complement Alternat Med 2013;2013:746486.
  11. Chan KK, Yao TJ, Jones B, Zhao JF, Ma FK, Leung CY, et al. The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol 2011;22(10):2241-9. https://doi.org/10.1093/annonc/mdq749
  12. Wu YH, Chen HY, Lai CH, Yeh CS, Pang JS, Qiu JT, et al. Use of Chinese Herbal Medicine Improves Chemotherapy-Induced Thrombocytopenia among Gynecological Cancer Patients: An Observational Study. Evid Based Complement Alternat Med 2018;2018:4201325.
  13. Wang R, Sun Q, Wang F, Liu Y, Li X, Chen T, et al. Efficacy and Safety of Chinese Herbal Medicine on Ovarian Cancer After Reduction Surgery and Adjuvant Chemotherapy: A Systematic Review and Meta-Analysis. Front Oncol 2019;9:730. https://doi.org/10.3389/fonc.2019.00730
  14. Kim KS, Choi HS, Kim SM, Yoo HS. Clinical Practice Guideline for Korean Medicine for Ovarian Cancer. J of Kor Traditional Oncologyl 2016;21(2):37-50.
  15. Zheng HM, Lee YW, Yoo HS, Cho CK. Case Study of a Breast Cancer Patient Accompanying with Hot Flush by Tamoxifen Whose Condition Was Improved by Jayeumganghwa-tang. Korean J Orient Int Med 2010;31(2):395-400.
  16. Wang Z, Qi F, Cui Y, Zhao L, Sun X, Tang W, et al. An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics. Biosci Trends 2018;12(3):220-39. https://doi.org/10.5582/bst.2018.01144
  17. Qi F, Zhao L, Zhou A, Zhang B, Li A, Wang Z, et al. The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer. Biosci Trends 2015 Feb;9(1):16-34. https://doi.org/10.5582/bst.2015.01019
  18. Shankar A, Roy S, Bhandari M, Rath GK, Biswas AS, Kanodia R, et al. Current Trends in Management of Oral Mucositis in Cancer Treatment. Asian Pac J Cancer Prev 2017;18(8):2019-26.
  19. Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol 2017;81(6):772-81. https://doi.org/10.1002/ana.24951
  20. Scully C, Sonis S, Diz PD. Oral mucositis. Oral Dis 2006 May;12(3):229-41. https://doi.org/10.1111/j.1601-0825.2006.01258.x
  21. Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol Oncol 2016;140(1):176-83. https://doi.org/10.1016/j.ygyno.2015.11.011
  22. Avan A, Postma TJ, Ceresa C, Avan Am Cavaletti G, Giovannetti E, et al. Platinum -induced neurotoxicity and preventive strategies: past, present, and future. Oncologist 2015;20(4):411-32. https://doi.org/10.1634/theoncologist.2014-0044
  23. Kuriyama A, Endo K. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Support Care Cancer 2018;26(4):1051-9. https://doi.org/10.1007/s00520-017-4028-6
  24. Hoshino N, Ganeko R, Hida K, Sakai Y. Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Int J Clin Oncol 2018;23(3):434-42. https://doi.org/10.1007/s10147-017-1229-4
  25. Nishikawa K, Aoyama T, Oba MS, Yoshikawa T, Matsuda C, Munemoto Y, et al. The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C). J Cancer 2018;9(10):1725-30. https://doi.org/10.7150/jca.24733
  26. He DY, Dai SM. Anti-inflammatory and immunomodulatory effects of paeonia lactiflora pall. a traditional chinese herbal medicine. Front Pharmacol 2011;2:10. https://doi.org/10.3389/fphar.2011.00010
  27. Chen XP, Li W, Xiao XF, Zhang LL, Liu CX. Phytochemical and pharmacological studies on Radix Angelica sinensis. Chin J Nat Med 2013;11(6):577-87. https://doi.org/10.1016/S1875-5364(13)60067-9
  28. Zhu B, Zhang QL, Hua JW, Cheng WL, Qin LP. The traditional uses, phytochemistry, and pharmacology of Atractylodes macrocephala Koidz : A review. J Ethnopharmacol 2018;226:143-67. https://doi.org/10.1016/j.jep.2018.08.023
  29. Wang Y, Dan Y, Yang D, Hu Y, Zhang L, Zhang C, et al. The genus Anemarrhena Bunge: A review on ethnopharmacology, phytochemistry and pharmacology. J Ethnopharmacol 2014;153(1):42-60. https://doi.org/10.1016/j.jep.2014.02.013
  30. Guan F, Lam W, Hu R, Kim YK, Han H, Cheng YC. Majority of Chinese Medicine Herb Category "Qing Re Yao" Have Multiple Mechanisms of Anti-inflammatory Activity. Sci Rep 2018 May 9;8(1):7416. https://doi.org/10.1038/s41598-018-25813-x
  31. Liu T, Zhang L, Joo D, Sun SC. NF-${\kappa}B$ signaling in inflammation. Signal Transduct Target Ther 2017;2:17023. https://doi.org/10.1038/sigtrans.2017.23
  32. Zhang Q, Lenardo MJ, Baltimore D. 30 Years of NF-${\kappa}B$: A Blossoming of Relevance to Human Pathobiology. Cell 2017;168(1-2):37-57. https://doi.org/10.1016/j.cell.2016.12.012
  33. Wang C, Wang P, Ouyang H, Wang J, Sun L, Li Y, et al. Efficacy of Traditional Chinese Medicine in Treatment and Prophylaxis of Radiation-Induced Oral Mucositis in Patients Receiving Radiotherapy: A Randomized Controlled Trial. Integr Cancer Ther 2017;17(2):444-50. https://doi.org/10.1177/1534735417725578
  34. Cheng YY, Hsieh CH, Tsai TH. Concurrent administration of anticancer chemotherapy drug and herbal medicine on the perspective of pharmacokinetics. J Food Drug Anal 2018 Apr;26(2S):S88-S95. https://doi.org/10.1016/j.jfda.2018.01.003
  35. Jeung CW, Jo HG, Seol JU. Current Status of Clinical Study on Traditional East Asian Medicine Using Taiwan Health Insurance Claim Data. Journal of Korean Medicine Rehabilitation 2017;27(2):67-75. https://doi.org/10.18325/jkmr.2017.27.2.67
  36. Lin FX, Tian LF, Lei CY, Ding CC, Shi L, Zhang SF. Chinese medicine for outcomes in colorectal cancer patients: A retrospective clinical study. Chin J Integr Med 2017;23(9):648-53. https://doi.org/10.1007/s11655-016-2581-3
  37. Jiao L, Dong C, Liu J, Chen Z, Zhang L, Xu J, et al. Effects of Chinese Medicine as Adjunct Medication for Adjuvant Chemotherapy Treatments of Non-Small Cell Lung Cancer Patients. Sci Rep 2017;7:46524. https://doi.org/10.1038/srep46524
  38. Ramos-Esquivel A, Viquez-Jaikel A, Fernandez C. Potential Drug-Drug and Herb-Drug Interactions in Patients With Cancer: A Prospective Study of Medication Surveillance. J Oncol Pract 2017; 13(7):613-22.

피인용 문헌

  1. 한약에 대한 N-of-1 임상시험의 현황 - 문헌 고찰 vol.41, pp.1, 2019, https://doi.org/10.13048/jkm.20008